Chrono Therapeutics, the maker of a wearable, smartphone-connected drug delivery device for smoking cessation, has completed a small randomized trial that shows that nicotine replacement therapy delivered with its device can reduce cravings to a statistically significant degree compared to a placebo delivered the same way.
The trial was a randomized, double-blinded study of 24 adult men who...
Chrono Therapeutics, a Hayward, California-based company working on a new wearable for smoking cessation and drug delivery, has raised $32 million in its first round of funding. The round was led by Canaan Partners and 5 am Ventures. Additional contributors included Fountain Healthcare Partners, and two strategic investors: GE Ventures and the Mayo Clinic.
The company's flagship product SmartStop...
